Ranbaxy a multi-bagger stock: Mukadam

39818 Investors following Ranbaxy Labs. Share this News with them.

0

Like this story, share it with millions of investors on M3

Ranbaxy a multi-bagger stock: Mukadam

Shahina Mukadam, IDBI Capital Market is of the view that Ranbaxy is going to be multi-bagger stock. Its numbers were very much in line as per expectations. Analyst positive on the prospects of the company going forward.

Post your opinion here

 

0

Tweet

Share on Tumblr

Excerpts from Bazaar on CNBC-TV18 Watch the full show » RELATED NEWS Ranbaxy Q4 net profit up at Rs 301.60 cr Expect 10-15% upside in Ranbaxy: Srivastava Ranbaxy Q4 net seen down 10% at Rs 165 cr Sell Ranbaxy Laboratories: Mohoni ALSO READ See previous views by Shahina Mukadam See what other Experts & Brokerages are saying about Ranbaxy Labs See messages about Ranbaxy Labs Ranbaxy Labs BSE | NSE 28/05/12 Are Mutual Funds betting on Ranbaxy Labs?

Shahina Mukadam , IDBI Capital Market is of the view that Ranbaxy is going to be multi-bagger stock.

Mukadam told CNBC-TV18, "Ranbaxy's numbers were very much in line to just what we had expected. The management has met whatever they had set out to do in the beginning of the year. I am pretty positive on the prospects of the company going forward. They have guided again 20% growth in profitability with a 17-18% topline growth, which is pretty healthy. They have also been talking about some good income coming from the settlement of a patent challenge."

She further added, "I remain positive on the stock going forward from here for a little longer term, 2-3 year prospective, where they have big product, which was atorvastatin, generic on which they have some bit of exclusivity and I think that is going to be a real blockbuster for the company. I would be buying this stock on every dips for the next 2-3 years and I think it's going to be a multi-bagger stock."